PURPOSE: Imaging using positron emission tomography (PET) in the field of nuclear medicine is becoming increasingly important. The aim of this study was to develop a method for labeling of affibody molecules with radiocobalt for PET applications. PROCEDURES: The human epidermal growth factor receptors type 2 (HER2) binding affibody molecule DOTA-Z(2395)-C was radiolabeled with (57)Co (used as a surrogate of (55)Co). The binding specificity and cellular processing of the labeled compound was studied in vitro followed by in vivo characterization in normal and tumor-bearing mice. Furthermore, a comparative biodistribution study was performed with a (111)In-labeled counterpart. RESULTS: DOTA-Z(2395)-C was successfully labeled with radiocobalt with nearly quantitative yield. The compound displayed good retention on cells over time and high tumor accumulation of radioactivity in animal studies. Imaging studies showed clear visualization of HER2-positive tumors. Furthermore, the radiocobalt label provided better tumor-to-organ ratios than (111)In. CONCLUSIONS: Radiocobalt is a promising label for affibody molecules for future PET applications.
PURPOSE: Imaging using positron emission tomography (PET) in the field of nuclear medicine is becoming increasingly important. The aim of this study was to develop a method for labeling of affibody molecules with radiocobalt for PET applications. PROCEDURES: The human epidermal growth factor receptors type 2 (HER2) binding affibody molecule DOTA-Z(2395)-C was radiolabeled with (57)Co (used as a surrogate of (55)Co). The binding specificity and cellular processing of the labeled compound was studied in vitro followed by in vivo characterization in normal and tumor-bearing mice. Furthermore, a comparative biodistribution study was performed with a (111)In-labeled counterpart. RESULTS: DOTA-Z(2395)-C was successfully labeled with radiocobalt with nearly quantitative yield. The compound displayed good retention on cells over time and high tumor accumulation of radioactivity in animal studies. Imaging studies showed clear visualization of HER2-positive tumors. Furthermore, the radiocobalt label provided better tumor-to-organ ratios than (111)In. CONCLUSIONS: Radiocobalt is a promising label for affibody molecules for future PET applications.
Authors: Anna Orlova; Thuy Tran; Charles Widström; Torun Engfeldt; Amelie Eriksson Karlström; Vladimir Tolmachev Journal: Int J Mol Med Date: 2007-09 Impact factor: 4.101
Authors: Vladimir Tolmachev; Anna Orlova; Fredrik Y Nilsson; Joachim Feldwisch; Anders Wennborg; Lars Abrahmsén Journal: Expert Opin Biol Ther Date: 2007-04 Impact factor: 4.388
Authors: R Simon; A Nocito; T Hübscher; C Bucher; J Torhorst; P Schraml; L Bubendorf; M M Mihatsch; H Moch; K Wilber; A Schötzau; J Kononen; G Sauter Journal: J Natl Cancer Inst Date: 2001-08-01 Impact factor: 13.506
Authors: Anna Orlova; Mikaela Magnusson; Tove L J Eriksson; Martin Nilsson; Barbro Larsson; Ingmarie Höidén-Guthenberg; Charles Widström; Jörgen Carlsson; Vladimir Tolmachev; Stefan Ståhl; Fredrik Y Nilsson Journal: Cancer Res Date: 2006-04-15 Impact factor: 12.701
Authors: Jered C Garrison; Tammy L Rold; Gary L Sieckman; Said Daibes Figueroa; Wynn A Volkert; Silvia S Jurisson; Timothy J Hoffman Journal: J Nucl Med Date: 2007-07-13 Impact factor: 10.057
Authors: Gang Ren; Jack M Webster; Zhe Liu; Rong Zhang; Zheng Miao; Hongguang Liu; Sanjiv S Gambhir; Faisal A Syud; Zhen Cheng Journal: Amino Acids Date: 2011-10-08 Impact factor: 3.520
Authors: H F Valdovinos; R Hernandez; S Graves; P A Ellison; T E Barnhart; C P Theuer; J W Engle; W Cai; R J Nickles Journal: Appl Radiat Isot Date: 2017-09-06 Impact factor: 1.513
Authors: Vladimir Tolmachev; Daniel Rosik; Helena Wållberg; Anna Sjöberg; Mattias Sandström; Monika Hansson; Anders Wennborg; Anna Orlova Journal: Eur J Nucl Med Mol Imaging Date: 2009-10-17 Impact factor: 9.236
Authors: Filippa Fleetwood; Susanne Klint; Martin Hanze; Elin Gunneriusson; Fredrik Y Frejd; Stefan Ståhl; John Löfblom Journal: Sci Rep Date: 2014-12-17 Impact factor: 4.379
Authors: Javad Garousi; Ken G Andersson; Johan H Dam; Birgitte B Olsen; Bogdan Mitran; Anna Orlova; Jos Buijs; Stefan Ståhl; John Löfblom; Helge Thisgaard; Vladimir Tolmachev Journal: Sci Rep Date: 2017-07-20 Impact factor: 4.379
Authors: Joanna Strand; Hadis Honarvar; Anna Perols; Anna Orlova; Ram Kumar Selvaraju; Amelie Eriksson Karlström; Vladimir Tolmachev Journal: PLoS One Date: 2013-08-01 Impact factor: 3.240